China Commits To Patent Linkage And Extensions In US Trade Deal
Data Protection Also Included In Deal
Executive Summary
The first phase of a major trade agreement just signed by the US and China obliges the latter to implement a system linking pharma patent enforcement to marketing authorization procedures as well as to offer patent-term extensions.
You may also be interested in...
China Unlikely To Be Included In US FDA's Project Orbis In The Near Term
Oncology Center of Excellence Director Pazdur says there must be confidence that confidentiality agreements are universally accepted in response to request that China be included in the multi-regulator application assessment program.
Coronavirus Not Impacting Rx Manufacturing Supply Chain – Yet
US FDA’s drug shortage team continues to check in with sponsors, but so far the infections and quarantines have not impacted drug production.
Trade, IP And Oncology Deals: What You Need To Know About China And JPM20
China was a focus of discussions at the 2020 J.P. Morgan Healthcare Conference, as a Phase One trade agreement was signed to end a 17-month dispute with the US. Patent linkage and IP protection enforcement are also being closely watched, while Chinese firms including BeiGene continue to make strides in oncology deal-making.